{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:21Z","timestamp":1791357261906,"version":"4.3.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015756","name":"Cilag","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004337","name":"St. George's, University of London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.schres.2019.08.001","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T00:04:39Z","timestamp":1565827479000},"page":"234-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Clozapine, a controversial gold standard antipsychotic for the 21st century: Switching to paliperidone palmitate 3-monthly improves the metabolic profile and lowers antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort"],"prefix":"10.1016","volume":"212","author":[{"given":"Juan Andr\u00e9s","family":"Mart\u00ednez-Andr\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio","family":"Garc\u00eda-Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2019.08.001_bb0005","series-title":"Benzodiazepines: How They Work and How to Withdrawn. Paperback","author":"Ashton","year":"2006"},{"key":"10.1016\/j.schres.2019.08.001_bb0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.schres.2017.01.002","article-title":"Efficacy, acceptability and tolerability of 8 atypical antipsychotics in Chinese patients with acute schizophrenia: a network meta-analysis","volume":"185","author":"Bai","year":"2017","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2019.08.001_bb0015","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5455\/medarh.2017.72.112-115","article-title":"Serum gamma\u2011glutamyltransferase and obesity: is there a link?","volume":"72","author":"Coku","year":"2018","journal-title":"Med Arch"},{"key":"10.1016\/j.schres.2019.08.001_bb0020","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/bcp.12565","article-title":"Drug-induced liver injury: results from the hospital-based Berlin Case\u2013Control Surveillance Study","volume":"79","author":"Douros","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.schres.2019.08.001_bb0025","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/03007995.2018.1560220","article-title":"Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans","volume":"35","author":"Emond","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"10.1016\/j.schres.2019.08.001_bb0030","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/JCP.0000000000000794","article-title":"Effective switch from clozapine to aripiprazole in treatment-resistant schizophrenia and comorbid alcohol use disorder","volume":"37","author":"Feeley","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.schres.2019.08.001_bb0035","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2019.08.001_bb0040","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1161\/01.ATV.0000251993.20372.40","article-title":"Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk","volume":"27","author":"Lee","year":"2007","journal-title":"The Framingham Heart Study. Arterioscl Throm Vas"},{"key":"10.1016\/j.schres.2019.08.001_bb0045","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/schbul\/sbv037","article-title":"Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method","volume":"41","author":"Leucht","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2019.08.001_bb0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/JCP.0b013e31828700c7","article-title":"Switching from clozapine to zotepine in patients with schizophrenia: a 12-week prospective, randomized, rater blind, and parallel study","volume":"33","author":"Lin","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.schres.2019.08.001_bb0055","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40261-018-0647-z","article-title":"Paliperidone palmitate 3-monthly versus 1-monthly injectable in patients with schizophrenia with or without prior exposure to oral risperidone or paliperidone: a post hoc, subgroup analysis","volume":"38","author":"Mathews","year":"2018","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.schres.2019.08.001_bb0060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/YIC.0b013e328303ac75","article-title":"Is the defined daily dose system a reliable tool for standardizing antipsychotic dosages?","volume":"23","author":"Nos\u00e8","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2019.08.001_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eurpsy.2013.08.001","article-title":"Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia","volume":"29","author":"Schneider","year":"2014","journal-title":"Eur Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2019.08.001_bb0070","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0706743717718167","article-title":"Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis","volume":"62","author":"Siskind","year":"2017","journal-title":"Can. J. Psychiatr."},{"issue":"7","key":"10.1016\/j.schres.2019.08.001_bb0075","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29.823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996419303421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996419303421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:30:50Z","timestamp":1760297450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996419303421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":15,"alternative-id":["S0920996419303421"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2019.08.001","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clozapine, a controversial gold standard antipsychotic for the 21st century: Switching to paliperidone palmitate 3-monthly improves the metabolic profile and lowers antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2019.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}